NY-ESO-1 (c259) TCR-T Cells
The NY-ESO-1 (c259) TCR-T Cells are generated by high-titer lentiviral transduction of human primary CD4+ and CD8+ T cells with NY-ESO-1-Specific TCR Lentivirus (Clone c259) (#78676). These ready-to-use TCR (T cell receptor) -T cells express the human TCR clone c259, that specifically recognizes the antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1).
These TCR-T cells have been validated by flow cytometry (to determine the TCR expression) and co-culture assays (IFN-γ staining and degranulation).
Figure 1: Construct diagram showing components of the NY-ESO-1-specific TCR expressed in NY-ESO-1 (c259) TCR-T Cells.
TRAV and TRAC correspond to the TCR alpha chain variable and constant regions, respectively, whereas TRBV and TRBC correspond to the TCR beta chain variable and constant regions
| Name | Ordering Information |
| Human Interleukin-2 Recombinant | BPS Bioscience #90184 |
| Human CD3/CD28/CD2 T Cell Activator | Stemcell Technologies #10970 |
| T2 Cell Line | ATCC #CRL-1992 |
| MAGE-A4 Peptide (230-239) | BPS Bioscience #78966 |
| NY-ESO-1 Peptide (157-165) | BPS Bioscience #78758 |
| APC MHC I Dextramer (HLA-A*02:01 SLLMWITQV) | Immudex #WB03247 |
| Untransduced T Cells (Negative Control for TCR-T) | BPS Bioscience #78989 |
| Anti-CD8 Antibody, FITC | BPS Bioscience #102224 |
| APC anti-human CD107a (LAMP-1) Antibody | BioLegend #328620 |
| APC anti-human IFN-γ | BioLegend #986702 |
| Monensin sodium | Medchem #HY-N0150 |
| Brefeldin A | Medchem #HY-16592 |
| Cell Staining Buffer | BioLegend #420201 |
| Fixation Buffer | BioLegend #420801 |
| Permeabilization Wash Buffer | BioLegend #421002 |
Recommended TCR-T Cell Medium: TCellM™ (#78753) supplemented with 10 ng/ml Interleukin-2 (#90184).
The cells have been screened to confirm the absence of Mycoplasma species.
NY-ESO-1 (New York esophageal squamous cell carcinoma 1), also known as Cancer/testis antigen 1 or CTAG1B, is an important tumorigenic marker present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but is re-expressed in multiple myeloma, non-small cell lung carcinoma (NSCLC), and breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors.
Thomas R., et al., 2018 Front. Immunol. 9: 00947.
Raza A., et al., 2020 J. of Translational Medicine 140.
Kropp KN., et al., 2020 PLOS One 15(9): e0238875.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.